Intelligence Feed event · Equity · 2026-10-07

    Oculis Schedules Licaminlimab Data at AAO Ahead of Year-End Registrational Readout

    Question

    Oculis Schedules Licaminlimab Data at AAO Ahead of Year-End Registrational Readout

    Direct answer

    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will showcase Licaminlimab during the Eyecelerator conference at AAO 2026 on October 8. Licaminlimab is under clinical evaluation as a topical ophthalmic anti-TNF alpha therapy designed to treat dry eye disease characterized by TNFR1 genetic markers. The company confirmed that its registrational PREDICT-1 clinical trial is progressing on schedule, with topline data readout expected around the end of 2026. The presentation will outline trial design and biomarker-driven patient selection parameters.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis Schedules Licaminlimab Data at AAO Ahead of Year-End Registrational Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-schedules-licaminlimab-data-at-aao-ahead-of-year-end-registrational-reado-fcfe15

    EQUITY
    Oculis Schedules Licaminlimab Data at AAO Ahead of Year-End Registrational Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will showcase Licaminlimab during the Eyecelerator conference at AAO 2026 on October 8. Licaminlimab is under clinical evaluation as a topical ophthalmic anti-TNF alpha therapy designed to treat dry eye disease characterized by TNFR1 genetic markers. The company confirmed that its registrational PREDICT-1 clinical trial is progressing on schedule, with topline data readout expected around the end of 2026. The presentation will outline trial design and biomarker-driven patient selection parameters.
    OCS
    Impact
    59
    OCT 7
    SIG
    88%
    OCS
    Oculis Schedules Licaminlimab Data at AAO Ahead of Year-End Registrational Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will showcase Licaminlimab during the Eyecelerator conference at AAO 2026 on October 8. Licaminlimab is under clinical evaluation as a topical ophthalmic anti-TNF alpha therapy designed to treat dry eye disease characterized by TNFR1 genetic markers. The company confirmed that its registrational PREDICT-1 clinical trial is progressing on schedule, with topline data readout expected around the end of 2026. The presentation will outline trial design and biomarker-driven patient selection parameters.
    → Clinical trial milestone progress transmits pipeline valuation into OCS equity ahead of year-end PREDICT-1 phase readout.
    Impact
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will showcase Licaminlimab during the Eyecelerator conference at AAO 2026 on October 8. Licaminlimab is under clinical evaluation as a topical ophthalmic anti-TNF alpha therapy designed to treat dry eye disease characterized by TNFR1 genetic markers. The company confirmed that its registrational PREDICT-1 clinical trial is progressing on schedule, with topline data readout expected around the end of 2026. The presentation will outline trial design and biomarker-driven patient selection parameters.
    Affected
    OCS
    Transmission
    Clinical trial milestone progress transmits pipeline valuation into OCS equity ahead of year-end PREDICT-1 phase readout.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSbiopharma pipeline clinical event timelineWatch1-3mOculis announced conference presentation date and year-end trial readout guidance.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month